Vendel A. Kristensen

  • Consultant, Postdoc; MD

Education:

  • MD University of Bergen (2001)
  • PhD University of Oslo (2016)
  • Norwegian clinical specialist accreditations: Internal medicine (2012) and gastroenterology (2017)

Current position:

Consultant, Department of gastroenterology, Oslo University Hospital

 

Publications 2024

Holten KA, Bernklev T, Opheim R, Olsen BC, Detlie TE, Strande V, Ricanek P, Boyar R, Bengtson MB, Aabrekk TB, Asak Ø, Frigstad SO, Kristensen VA, Hagen M, Henriksen M, Huppertz-Hauss G, Høivik ML, Jelsness-Jørgensen LP (2024)
Fatigue in patients with inflammatory bowel disease in remission one year after diagnosis (the IBSEN III study)
J Crohns Colitis (in press)
DOI 10.1093/ecco-jcc/jjae170, PubMed 39527064

Lund C, Strande V, Hagen M, Bengtson MB, Boyar R, Detlie TE, Frigstad SO, Medhus AW, Henriksen M, Holten KIA, Hovde Ø, Huppertz-Hauss G, Johansen I, Olsen BC, Opheim R, Pallenschat J, Perminow G, Ricanek P, Torp R, Ystrøm CM, Høie O, Asak Ø, Vatn S, Aabrekk TB, Kristensen VA et al. (2024)
Low Surgery Rates in Early Crohn's Disease: Results from a Prospective Population-Based Inception Cohort-The Inflammatory Bowel Disease in South-Eastern Norway III Study
Inflamm Bowel Dis (in press)
DOI 10.1093/ibd/izae297, PubMed 39699202

Strande V, Høivik ML, Kristensen VA (2024)
Letter: Critical appraisal of biologic therapy in early ulcerative colitis management-Addressing study limitations and the role of psychological resilience-Authors' reply
Aliment Pharmacol Ther, 60 (6), 831-832
DOI 10.1111/apt.18187, PubMed 39072820

Strande V, Lund C, Hagen M, Bengtson MB, Cetinkaya RB, Detlie TE, Frigstad SO, Høie O, Medhus AW, Henriksen M, Aass Holten KI, Hovde Ø, Huppertz-Hauss G, Johansen I, Olsen BC, Opheim R, Ricanek P, Torp R, Tønnessen T, Vatn S, Aabrekk TB, Høivik ML, Kristensen VA (2024)
Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis-results from the IBSEN III inception cohort
Aliment Pharmacol Ther, 60 (3), 357-368
DOI 10.1111/apt.18097, PubMed 38837289

Zerouga I, Valeur J, Sommer C, Cvancarova Småstuen M, Medhus AW, Lund C, Johansen I, Cetinkaya RB, Bengtson MB, Torp R, Hovde Ø, Huppertz-Hauss G, Detlie TE, Aabrekk TB, Ricanek P, Frigstad SO, Hopstock LA, Opheim R, Kristensen VA, Høivik ML, Hauger Carlsen M, Aas AM (2024)
Dietary intake and nutritional status in patients with newly diagnosed inflammatory bowel disease: insights from the IBSEN III study
Scand J Gastroenterol, 59 (6), 652-660
DOI 10.1080/00365521.2024.2313056, PubMed 38356408

Publications 2023

Evensen H, Sandstad O, Larssen L, Hagen M, Kristensen VA, Søvik TT, Schulz A, Hauge T, Medhus AW (2023)
Intraoperative distensibility measurement in POEM for achalasia: impact on patient outcome and associations with other outcome variables at 1-year follow-up
Surg Endosc, 37 (12), 9283-9290
DOI 10.1007/s00464-023-10494-z, PubMed 37880446

Holten KIA, Bernklev T, Opheim R, Johansen I, Olsen BC, Lund C, Strande V, Medhus AW, Perminow G, Bengtson MB, Cetinkaya RB, Vatn S, Frigstad SO, Aabrekk TB, Detlie TE, Hovde Ø, Kristensen VA, Småstuen MC, Henriksen M, Huppertz-Hauss G, Høivik ML, Jelsness-Jørgensen LP (2023)
Fatigue in Patients with Newly Diagnosed Inflammatory Bowel Disease: Results from a Prospective Inception Cohort, the IBSEN III Study
J Crohns Colitis, 17 (11), 1781-1790
DOI 10.1093/ecco-jcc/jjad094, PubMed 37279652

Johansen I, Småstuen MC, Løkkeberg ST, Kristensen VA, Høivik ML, Lund C, Olsen B, Strande V, Huppertz-Hauss G, Aabrekk TB, Bengtson MB, Ricanek P, Detlie TE, Frigstad SO, Jelsness-Jørgensen LP, Opheim R (2023)
Symptoms and symptom clusters in patients newly diagnosed with inflammatory bowel disease: results from the IBSEN III Study
BMC Gastroenterol, 23 (1), 255
DOI 10.1186/s12876-023-02889-y, PubMed 37501083

Olsen BC, Opheim R, Kristensen VA, Høivik ML, Lund C, Aabrekk TB, Johansen I, Holten K, Strande V, Bengtson MB, Ricanek P, Detlie TE, Bernklev T, Jelsness-Jørgensen LP, Huppertz-Hauss G (2023)
Health-related quality of life in patients with newly diagnosed inflammatory bowel disease: an observational prospective cohort study (IBSEN III)
Qual Life Res, 32 (10), 2951-2964
DOI 10.1007/s11136-023-03435-9, PubMed 37219727

Publications 2022

Evensen H, Hjermstad MJ, Cvancarova M, Kristensen V, Larssen L, Skattum J, Hauge T, Sandstad O, Medhus AW (2022)
Quality of life in patients with achalasia: Associations with Eckardt score and objective treatment outcomes after peroral endoscopic myotomy
Endosc Int Open, 10 (12), E1570-E1576
DOI 10.1055/a-1968-7682, PubMed 36531682

Publications 2021

Evensen H, Småstuen MC, Schulz A, Kristensen V, Larssen L, Skattum J, Sandstad O, Hauge T, Medhus AW (2021)
One year comprehensive prospective follow-up of achalasia patients after peroral endoscopic myotomy
Ann Med, 53 (1), 2225-2233
DOI 10.1080/07853890.2021.2005253, PubMed 34806501

Kristensen VA, Opheim R, Perminow G, Huppertz-Hauss G, Detlie TE, Lund C, Andersen S, Olsen BC, Johansen I, Medhus AW, Vatn S, Brackmann S, Olbjørn C, Rove J, Henriksen M, Løvlund EE, Bengtson MB, Aabrekk TB, Tønnessen T, Vikskjold FB, Yassin H, Frigstad SO, Hasund A, Høie O, Schmidt K et al. (2021)
Inflammatory bowel disease in South-Eastern Norway III (IBSEN III): a new population-based inception cohort study from South-Eastern Norway
Scand J Gastroenterol, 56 (8), 899-905
DOI 10.1080/00365521.2021.1922746, PubMed 34154494

Publications 2020

Kristensen VA, Cvancarova M, Høivik ML, Moum B, Vatn MH (2020)
Serological antibodies and surgery in a population-based inception cohort of Crohn's disease patients - the IBSEN study
Scand J Gastroenterol, 55 (4), 436-441
DOI 10.1080/00365521.2020.1745879, PubMed 32252542

Publications 2019

Evensen H, Kristensen V, Larssen L, Sandstad O, Hauge T, Medhus AW (2019)
Outcome of peroral endoscopic myotomy (POEM) in treatment-naive patients. A systematic review
Scand J Gastroenterol, 54 (1), 1-7
DOI 10.1080/00365521.2018.1549271, PubMed 30650313

Kristensen VA, Valeur J, Brackmann S, Jahnsen J, Brunborg C, Tveito K (2019)
Attention deficit and hyperactivity disorder symptoms respond to gluten-free diet in patients with coeliac disease
Scand J Gastroenterol, 54 (5), 571-576
DOI 10.1080/00365521.2019.1608467, PubMed 31050907

Publications 2017

Kristensen V, Røseth A, Ahmad T, Skar V, Moum B (2017)
Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis
Gastroenterol Res Pract, 2017, 2098293
DOI 10.1155/2017/2098293, PubMed 29225617

Publications 2016

Kristensen V, Lauritzen T, Jelsness-Jørgensen LP, Frigstad SO, Corwin C, Moum B (2016)
Patient-performed extraction of faecal calprotectin
Clin Chem Lab Med, 54 (8), 1357-63
DOI 10.1515/cclm-2015-1037, PubMed 26812797

Publications 2015

Kristensen V, Klepp P, Cvancarova M, Røseth A, Skar V, Moum B (2015)
Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin
J Crohns Colitis, 9 (2), 164-9
DOI 10.1093/ecco-jcc/jju015, PubMed 25518057

Kristensen V, Lauritzen T, Jelsness-JØrgensen LP, Moum B (2015)
Validation of a new extraction device for measuring faecal calprotectin in inflammatory bowel disease, and comparison to established extraction methods
Scand J Clin Lab Invest, 75 (5), 355-61
DOI 10.3109/00365513.2015.1030765, PubMed 25856663

Kristensen V, Malmstrøm GH, Skar V, Røseth A, Moum B (2015)
Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure
Scand J Gastroenterol, 51 (5), 548-55
DOI 10.3109/00365521.2015.1117650, PubMed 26634305

Kristensen V, Moum B (2015)
Correspondence: fecal calprotectin and cut-off levels in inflammatory bowel disease
Scand J Gastroenterol, 50 (9), 1183-4
DOI 10.3109/00365521.2015.1025830, PubMed 25772406